The « Streinth » team aims at the development of more efficient and personalized therapies for stomach and head & neck cancers through a better understanding of the variability in the therapeutic response and the development of innovative molecules facilitating immunotherapy protocols.
A particular focus is made on the role of the family of the p53 tumor suppressor gene in the dynamic interactions between cancer cells and the tumour ecosystem – metabolic and cellular microenvironment and impacted healthy tissues (muscle, nervous system). To address these questions, we propose a translational research that includes fundamental molecular studies extending them into the pathophysiological context using animal models (i.e. transgenics gastric cancer mouse model, PDX: patient derived xenografts) and clinical investigations (i.e. biobanks for gastric and head/neck cancers). These models serve also for global and bioinformatics analyses by combining “deep RNA/DNA sequencing” and pre-existing “omics“ data (methylome, miRome, transcriptome, genetic anomalies) aiming at the identification without a priori of prognostic markers and therapeutic targets. Our results are the bases for the development of innovative mono or combined therapies targeting the cellular metabolism, which already led to several patents. In addition, we are animating an interdisciplinary international network including chemists specialized in organometallic chemistry to develop novel anticancer compounds.